About Shugoshin 2
Shugoshin 2 (SGO2) is a protein
from Homo sapiens identified by UniProt accession
Q562F6, 1265 residues long.
MolForge cross-references it against 0 known binders and
145 disease associations.
Target properties
| Protein name | Shugoshin 2 |
|---|
| UniProt accession | Q562F6 |
|---|
| Gene | SGO2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1265 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (145)
Diseases linked to this target (Open Targets).
- primary ovarian insufficiency · score 0.35
- Perrault syndrome · score 0.19
- lean body mass · score 0.11
- hepatocellular carcinoma · score 0.10
- body height · score 0.09
- azoospermia · score 0.09
- protein measurement · score 0.09
- male infertility with teratozoospermia due to single gene mutation · score 0.08
- partial chromosome Y deletion · score 0.08
- spermatogenic failure 25 · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q562F6-F1 | alphafold | PREDICTED | 42.80 | — |
Amino-acid sequence (1265 residues)
MECPVMETGS LFTSGIKRHL KDKRISKTTK LNVSLASKIK TKILNNSSIF KISLKHNNRA LAQALSREKE NSRRITTEKM LLQKEVEKLN FENTFLRLKL NNLNKKLIDI EALMNNNLIT AIEMSSLSEF HQSSFLLSAS KKKRISKQCK LMRLPFARVP LTSNDDEDED KEKMQCDNNI KSKTLPDIPS SGSTTQPLST QDNSEVLFLK ENNQNVYGLD DSEHISSIVD VPPRESHSHS DQSSKTSLMS EMRNAQSIGR RWEKPSPSNV TERKKRGSSW ESNNLSADTP CATVLDKQHI SSPELNCNNE INGHTNETNT EMQRNKQDLP GLSSESAREP NAECMNQIED NDDFQLQKTV YDADMDLTAS EVSKIVTVST GIKKKSNKKT NEHGMKTFRK VKDSSSEKKR ERSKRQFKNS SDVDIGEKIE NRTERSDVLD GKRGAEDPGF IFNNEQLAQM NEQLAQVNEL KKMTLQTGFE QGDRENVLCN KKEKRITNEQ EETYSLSQSS GKFHQESKFD KGQNSLTCNK SKASRQTFVI HKLEKDNLLP NQKDKVTIYE NLDVTNEFHT ANLSTKDNGN LCDYGTHNIL DLKKYVTDIQ PSEQNESNIN KLRKKVNRKT EIISGMNHMY EDNDKDVVHG LKKGNFFFKT QEDKEPISEN IEVSKELQIP ALSTRDNENQ CDYRTQNVLG LQKQITNMYP VQQNESKVNK KLRQKVNRKT EIISEVNHLD NDKSIEYTVK SHSLFLTQKD KEIIPGNLED PSEFETPALS TKDSGNLYDS EIQNVLGVKH GHDMQPACQN DSKIGKKPRL NVCQKSEIIP ETNQIYENDN KGVHDLEKDN FFSLTPKDKE TISENLQVTN EFQTVDLLIK DNGNLCDYDT QNILELKKYV TDRKSAEQNE SKINKLRNKV NWKTEIISEM NQIYEDNDKD AHVQESYTKD LDFKVNKSKQ KLECQDIINK HYMEVNSNEK ESCDQILDSY KVVKKRKKES SCKAKNILTK AKNKLASQLT ESSQTSISLE SDLKHITSEA DSDPGNPVEL CKTQKQSTTT LNKKDLPFVE EIKEGECQVK KVNKMTSKSK KRKTSIDPSP ESHEVMERIL DSVQGKSTVS EQADKENNLE NEKMVKNKPD FYTKAFRSLS EIHSPNIQDS SFDSVREGLV PLSVSSGKNV IIKENFALEC SPAFQVSDDE HEKMNKMKFK VNRRTQKSGI GDRPLQDLSN TSFVSNNTAE SENKSEDLSS ERTSRRRRCT PFYFKEPSLR DKMRR
Explore Shugoshin 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets